Serum response factor is overexpressed in esophageal squamous cell carcinoma and promotes Eca-109 cell proliferation and invasion

He,Xi; Xu,Hong; Zhao,Min; Wang,Shijie

doi:10.3892/ol.2013.1120

Serum response factor is overexpressed in esophageal squamous cell carcinoma and promotes Eca-109 cell proliferation and invasion

Authors:
- Xi He
- Hong Xu
- Min Zhao
- Shijie Wang
View Affiliations

Affiliations: Department of Surgery, Hebei Medical University Research Center, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Medical Research Center, Hebei United University, Tangshan, Hebei 063000, P.R. China, Department of Pathology, The Qinhuangdao First Hospital, Qinhuangdao, Hebei 066000, P.R. China
Published online on: January 9, 2013 https://doi.org/10.3892/ol.2013.1120
Pages: 819-824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies indicate that serum response factor (SRF) is highly expressed in tumors such as hepatocellular, thyroid, esophageal and lung carcinoma. However, the expression and roles of SRF in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, immunohistochemistry was used to compare the expression of SRF in ESCC cases (n=73) and normal controls (n=30). The RNA interference (RNAi) technique was used to knock down the expression of SRF in Eca-109 cells. Cell proliferation, cell cycle stage and invasion were measured with cell counting kit (CCK)-8, flow cytometry and Transwell assays, respectively. Western blotting was used to measure SRF, E-cadherin, β-catenin and cyclin D1 expression in Eca-109 cells treated with siRNA. The study demonstrated that human ESCC has increased expression of SRF. In addition, blocking SRF expression inhibited tumor proliferation and invasion. In conclusion, SRF has the potential to be a new marker for ESCC diagnosis and therapy.

View Figures

View References

1	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
2	No authors listed. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 5:517–526. 2008. View Article : Google Scholar
3	Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar : PubMed/NCBI
4	Tian X, Liu Z, Niu B, et al: E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011:5673052011. View Article : Google Scholar : PubMed/NCBI
5	Hu Q, Guo C, Li Y, Aronow BJ and Zhang J: LMO7 mediates cell-specific activation of the Rho-myocardin-related transcription factor-serum response factor pathway and plays an important role in breast cancer cell migration. Mol Cell Biol. 31:3223–3240. 2011. View Article : Google Scholar : PubMed/NCBI
6	Choi HN, Kim KR, Lee JH, et al: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep. 21:57–63. 2009.PubMed/NCBI
7	Farra R, Dapas B, Pozzato G, et al: Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie. 92:455–463. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kim KR, Bae JS, Choi HN, et al: The role of serum response factor in hepatocellular carcinoma: an association with matrix metalloproteinase. Oncol Rep. 26:1567–1572. 2011.PubMed/NCBI
9	Kim HJ, Kim KR, Park HS, et al: The expression and role of serum response factor in papillary carcinoma of the thyroid. Int J Oncol. 35:49–55. 2009.PubMed/NCBI
10	Kwon CY, Kim KR, Choi HN, et al: The role of serum response factor in hepatocellular carcinoma: implications for disease progression. Int J Oncol. 37:837–844. 2010.PubMed/NCBI
11	Park MY, Kim KR, Park HS, et al: Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol. 31:1309–1315. 2007.PubMed/NCBI
12	Zhe X, Yang Y and Schuger L: Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol. 32:28–34. 2005. View Article : Google Scholar : PubMed/NCBI
13	Rimerman RA, Gellert-Randleman A and Diehl JA: Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J Biol Chem. 275:14736–14742. 2000. View Article : Google Scholar : PubMed/NCBI
14	Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
15	Pradeep A, Sharma C, Sathyanarayana P, et al: Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene. 23:3689–3699. 2004. View Article : Google Scholar : PubMed/NCBI
16	Song BJ, Park YJ, Kim HS, Kim CN and Chang SH: Expression of beta-catenin and E-cadherin in early gastric cancer: correlation with clinicopathologic parameters. Korean J Gastroenterol. 43:82–89. 2004.(In Korean).
17	Jiang H, Xia J, Kang J, Ding Y and Wu W: Short hairpin RNA targeting beta-catenin suppresses cell proliferation and induces apoptosis in human gastric carcinoma cells. Scand J Gastroenterol. 44:1452–1462. 2009. View Article : Google Scholar : PubMed/NCBI
18	Luo KJ, Hu Y, Wen J and Fu JH: CyclinD1, p53, E-cadherin, and VEGF discordant expression in paired regional metastatic lymph nodes of esophageal squamous cell carcinoma: a tissue array analysis. J Surg Oncol. 104:236–243. 2011. View Article : Google Scholar : PubMed/NCBI